These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 10327209)

  • 1. Biodiversity and bioseparation of HIV-1 envelope glycoproteins.
    Shao Y; Lu Y
    Crit Rev Oncog; 1999; 10(1-2):1-16. PubMed ID: 10327209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular approaches to AIDS vaccine development using baculovirus expression vectors.
    Kang CY
    Methods Mol Biol; 1995; 39():295-315. PubMed ID: 7542523
    [No Abstract]   [Full Text] [Related]  

  • 3. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.
    AIDS Vaccine Evaluation Group 022 Protocol Team
    J Infect Dis; 2001 Feb; 183(4):563-70. PubMed ID: 11170981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does the key to a successful HIV type 1 vaccine lie among the envelope sequences of infected individuals?
    Rencher SD; Slobod KS; Dawson DH; Lockey TD; Hurwitz JL
    AIDS Res Hum Retroviruses; 1995 Sep; 11(9):1131-3. PubMed ID: 8554911
    [No Abstract]   [Full Text] [Related]  

  • 5. Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope.
    Haglund K; Forman J; Kräusslich HG; Rose JK
    Virology; 2000 Mar; 268(1):112-21. PubMed ID: 10683333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human immunodeficiency virus type 1 subtype E envelope recombinant peptides containing naturally immunogenic epitopes.
    Chang SY; Vithayasai V; Vithayasai P; Essex M; Lee TH
    J Infect Dis; 2000 Aug; 182(2):442-50. PubMed ID: 10915074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.
    Letvin NL; Huang Y; Chakrabarti BK; Xu L; Seaman MS; Beaudry K; Korioth-Schmitz B; Yu F; Rohne D; Martin KL; Miura A; Kong WP; Yang ZY; Gelman RS; Golubeva OG; Montefiori DC; Mascola JR; Nabel GJ
    J Virol; 2004 Jul; 78(14):7490-7. PubMed ID: 15220422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission.
    Derdeyn CA; Decker JM; Bibollet-Ruche F; Mokili JL; Muldoon M; Denham SA; Heil ML; Kasolo F; Musonda R; Hahn BH; Shaw GM; Korber BT; Allen S; Hunter E
    Science; 2004 Mar; 303(5666):2019-22. PubMed ID: 15044802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diversity considerations in HIV-1 vaccine selection.
    Gaschen B; Taylor J; Yusim K; Foley B; Gao F; Lang D; Novitsky V; Haynes B; Hahn BH; Bhattacharya T; Korber B
    Science; 2002 Jun; 296(5577):2354-60. PubMed ID: 12089434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype.
    Pal R; Kalyanaraman VS; Nair BC; Whitney S; Keen T; Hocker L; Hudacik L; Rose N; Mboudjeka I; Shen S; Wu-Chou TH; Montefiori D; Mascola J; Markham P; Lu S
    Virology; 2006 May; 348(2):341-53. PubMed ID: 16460776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in methods for the production, purification, and characterization of HIV-1 Gag-Env pseudovirion vaccines.
    Hammonds J; Chen X; Zhang X; Lee F; Spearman P
    Vaccine; 2007 Nov; 25(47):8036-48. PubMed ID: 17936444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positive response. Encouraging results in the search for an AIDS vaccine.
    Beardsley T
    Sci Am; 1991 Aug; 265(2):26. PubMed ID: 1862329
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluation of a new dot blot assay for confirmation of human immunodeficiency virus type 1 and 2 infections using recombinant p24, gp41, gp120 and gp36 antigens.
    Ravanshad M; Sabahi F; Mahboudi F; Kazemnejad A
    Saudi Med J; 2006 Jan; 27(1):31-6. PubMed ID: 16432590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
    Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
    J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombination property of the HIV-1 gp120 gene.
    Prljic J; Veljkovic N; Veljkovic V
    Int Rev Immunol; 2004; 23(5-6):447-54. PubMed ID: 15370276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralizing antibody induced in mice by novel glycoconjugates of human immunodeficiency virus type 1 gp120 and env2-3.
    Paoletti LC; Kennedy RC
    J Infect Dis; 2002 Dec; 186(11):1597-602. PubMed ID: 12447735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant vaccinia virus (LC16m8 strain) boost.
    Shinoda K; Xin KQ; Kojima Y; Saha S; Okuda K; Okuda K
    Clin Immunol; 2006 Apr; 119(1):32-7. PubMed ID: 16458074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model.
    Earl PL; Wyatt LS; Montefiori DC; Bilska M; Woodward R; Markham PD; Malley JD; Vogel TU; Allen TM; Watkins DI; Miller N; Moss B
    Virology; 2002 Mar; 294(2):270-81. PubMed ID: 12009868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity.
    Cham F; Zhang PF; Heyndrickx L; Bouma P; Zhong P; Katinger H; Robinson J; van der Groen G; Quinnan GV
    Virology; 2006 Mar; 347(1):36-51. PubMed ID: 16378633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Truncation of the human immunodeficiency virus-type-2 envelope glycoprotein allows efficient pseudotyping of murine leukemia virus retroviral vector particles.
    Höhne M; Thaler S; Dudda JC; Groner B; Schnierle BS
    Virology; 1999 Aug; 261(1):70-8. PubMed ID: 10441556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.